Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Daxdilimab by Amgen for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval
Daxdilimab is under clinical development by Amgen and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM). According to GlobalData,...
Daxdilimab by Amgen for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE): Likelihood of Approval
Daxdilimab is under clinical development by Amgen and currently in Phase II for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid...
Daxdilimab by Amgen for Dermatomyositis: Likelihood of Approval
Daxdilimab is under clinical development by Amgen and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs...
Daxdilimab by Amgen for Alopecia Areata: Likelihood of Approval
Daxdilimab is under clinical development by Amgen and currently in Phase II for Alopecia Areata. According to GlobalData, Phase II...